0 works0 citations0 h-index

Victoria P. Werth

California University of Pennsylvania(US)Philadelphia VA Medical Center(US)

Publications by Year

Research Areas

Systemic Lupus Erythematosus Research, Inflammatory Myopathies and Dermatomyositis, Autoimmune Bullous Skin Diseases, Urticaria and Related Conditions, T-cell and B-cell Immunology

Most-Cited Works

→ Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus(2012)5,184 cited
→ 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups(2017)1,469 cited
→ Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus(2016)841 cited
→ Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus(2008)577 cited
→ Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study(2016)491 cited
→ The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus

(2005)

490 cited

→ Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C‐HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF‐36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index‐2 (FI‐2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)(2011)434 cited

→ Update on morphea(2011)384 cited

→ Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts(2011)365 cited